New Vaccines and Chemotherapy

1. Front Matter

   Pages i-xxi

   PDF

2. Introduction

   1. Introduction

      • Joseph L. Melnick

      Pages 1-14

3. The New Generation of Virus Vaccines and Their Immunogenicity

   1. Front Matter

      Pages 15-15

      PDF

   2. Production of Viral Glycoproteins in Genetically Engineered Mammalian Cell Lines for Use as Vaccines against Herpes Simplex Virus and the Acquired Immune Deficiency Syndrome Retrovirus

      • Phillip W. Berman, Timothy Gregory, Donald Dowbenko, Laurence A. Lasky

      Pages 17-24

   3. Development of Fungal and Algal Cells for Expression of Herpes Virus Genes

      • W. C. Leung, E. K. Manavathu, J. Zwaagstra, K. Suryanarayana, S. E. Hasnain, M. F. K. Leung

      Pages 25-30

   4. Expression of Hepatitis B Virus Surface Antigen Gene in Mammalian, Yeast, and Insect Cells

      • C. Yong Kang, Thierry Vernet, David Y. Thomas

      Pages 31-42

   5. The Development of New Poliovirus Vaccines Based on Molecular Cloning

      • Akio Nomoto, Michinori Kohara, Shusuke Kuge, Shinobu Abe, Bert L. Semler, Toshihiko Komatsu et al.

      Pages 43-54

   6. Rotavirus

      • T. Vesikari, E. Isolauri, T. Ruuska, A. Delem, F. E. André

      Pages 55-62

   7. Expression of Hepatitis B Virus Surface Antigens Containing Pre-s Regions by Recombinant Vaccinia Viruses

      • Bernard Moss, Kuo-Chi Cheng, Geoffrey L. Smith

      Pages 63-67

   8. New Generation of Rabies Vaccine

      • T. J. Wiktor, M. P. Kieny, R. Lathe

      Pages 69-90

4. Vaccination with Synthetic Peptides

   1. Front Matter

      Pages 91-91

      PDF

   2. Synthetic Peptides as Immunogens

      • F. Brown

      Pages 93-106

   3. Vaccination with Synthetic Hepatitis B Virus Peptides

      • A. R. Neurath, S. B. H. Kent, N. Strick, K. Parker

      Pages 107-128

   4. Chemical Synthesis of Poliovirus Peptides and Neutralizing Antibody Responses

      • Michael G. Murray, Eckard Wimmer

      Pages 129-140

   5. Immune Responses to Synthetic Peptide Vaccines of Veterinary Importance

      • P. Frenchick, M. I. Sabara, M. K. Ijaz, L. A. Babiuk

      Pages 141-151

5. Quality Control, Potency, and Standardization of Viral Vaccines

   1. Front Matter

      Pages 153-153

      PDF

   2. Production and Quality-Control Testing of Virus Vaccines for Use in Humans

      • J. Furesz, D. W. Boucher, G. Contreras

      Pages 155-171

   3. Potency Assay of Inactivated Influenza and Poliovaccine

      • J. M. Wood, G. C. Schild, P. D. Minor, D. I. Magrath, Jennifer Mumford, R. G. Webster

      Pages 173-186

   4. Rabies Vaccine Potency and Stability Testing

      • Morag Ferguson, Valerie Seagroatt, G. C. Schild

      Pages 187-193

   5. Hepatitis B Vaccine

      • A. Goudeau, F. Dubois, J. Klein, A. Godefroy, J. Huchet, Y. Brossard et al.

      Pages 195-208

Viral Vaccines Joseph L. Melnick As with history in general, the history of vaccines needs to be reexamined and updated. My task is to look back to see what has been successful and to look forward to see what remains to be accomplished in the prevention of viral diseases by vaccines. Also, I shall refer to the pertinent material discussed at two recent conferences of the Institute of Medicine, National Academy of Sciences, on virus vaccines under development and their target populations in the United States (1985b) and in developing countries (1986). These reports, plus a third on Vaccine Supply and Innovation (1985a), should be required reading for all those in both the public and the private sector who have a responsibility or interest in vaccines for the prevention of human disease. It has been through the development and use of vaccines that many viral diseases have been brought under control. The vaccines consist either of infectious living attenu­ ated viruses or of noninfectious killed viruses or subviral antigens. When we look at the record, it is the live vaccines that have given the great successes in controlling diseases around the world. Examples are smallpox, yellow fever, poliomyelitis, measles, mumps, and rubella.

• Antigen
• chemotherapy
• development
• diseases
• lake
• research
• vaccine
• virology
• virus

• University of Montreal, Montreal, Canada

  Edouard Kurstak

• University of Alberta, Edmonton, Canada

  R. G. Marusyk

• Centers for Disease Control, Atlanta, USA

  F. A. Murphy

• Institute of Molecular and Cellular Biology, Strasbourg, France

  M. H. V. Regenmortel

Policies and ethics